Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR 6MP vs Purinethol in Moderately Active Crohn's Disease
NCT01094613Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mercaptopurine in Crohn's disease (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Proportion of subjects with clinical response at study end at 12 weeks. Started Nov 2010; status: terminated.
02
Drugs
mercaptopurine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01094613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094613.